European Partnership PerMed

Strengthening personalized medicine Submissions: Nov. 4, 2026 to Jan. 20, 2027 The European Partnership for Personalized Medicine (EP PerMed) is a platform for the coordination of national and European activities in the field of personalized medicine. EP PerMed unites earlier European initiatives under one roof and is a continuation of the ERA PerMed program. The fourth call, “Personalised Medicine for Cell and Gene Therapy for Personalised Medicine (CGT4PM2027),” is scheduled to open on November 4, 2026. Target group The funding program is aimed at researchers working in the field of personalized medicine at universities, non-academic research institutions, and research departments in related sectors.  Funding goals EP PerMed aims to improve health outcomes within sustainable healthcare systems through research and the development, innovation, and implementation of personalized medicine approaches for the benefit of patients, citizens, and society. Information on the upcoming call “Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)”   This call is intended to support innovative research projects focusing on cell and gene therapy in personalized medicine. Research projects addressing all types of diseases are welcome. Proposals should address one or more of the following aspects: Somatic cell therapeutics Gene therapeutics Combined cell- and gene therapeutics Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles as vehicle for gene-based therapeutic procedure Please see the CGT4PM2027 website for the current list of participating countries. Approval Decided by the Scientific Board based on a recommendation of the Call Secretariat Funding institutions  Austrian Science Fund (FWF), Fonds Zukunft Österreich, co-funded by the European Union